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Abstract
Introduction: Breast fibroadenomata (FAD) are benign lesions which occur in about 10 % of all women. Diagnosis
is made by triple assessment (physical examination, imaging and/or histopathology/cytology). For a definitive diagnosis
of FAD, the treatment is conservative unless the patient is symptomatic. For symptomatic patients, the lumps can be
surgically excised or removed interventionally by vacuum-assisted mammotomy (VAM). Ablative techniques like
high-intensity focused ultrasound (HIFU), cryo-ablation and laser ablation have also been used for the treatment
of FAD, providing a minimally invasive treatment without scarring or poor cosmesis. This review summarises
current trials using minimally invasive ablative techniques in the treatment of breast FAD.
Methods: A comprehensive review of studies using minimally invasive ablative techniques was performed.
Results: There are currently several trials completed or recruiting patients using HIFU, cryo-ablation and laser
ablation in the treatment of breast FAD. The results look very promising but cannot be compared at this point
due to heterogeneity between studies.
Conclusion: Minimally invasive ablative techniques like HIFU, cryo-ablation and laser ablation are promising in
the treatment of breast FAD. Future trials should be randomised and contain larger numbers of patients to determine
the effectiveness of ablative techniques with more precision.
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Background
Breast fibroadenomata (FAD) are solitary, smooth, mobile
benign breast lesions that can occur at any age but most
often during the second and third decades [1–3]. Regres-
sion or complete resolution is seen in up to 59 % of cases
within 5 years [1]. FAD consist of combined proliferation
and epithelial and fibroblastic tissue elements which are
oestrogen-dependent and slowly growing [3]. FAD are be-
lieved to arise from breast lobulesin the ductal system of
the breast [2] FAD are usually diagnosed by standard
triple assessment which entails a physical examination,
imaging by ultrasound and/or mammogram and if the pa-
tient is 25 years or older, a cytological or histological con-
formation of the diagnosis [2, 3]. In the UK, management
of FAD is achieved via a multidisciplinary approach to en-
sure a more consistent approach to recommendation for
surgical and interventional excision [4]. Management of
non-symptomatic FAD is conservative once definitive
diagnosis is made [2]. Management of symptomatic FAD
consists of either conservative treatment, surgical excision
or vacuum-assisted mammotomy (VAM) [2]. These op-
tions are discussed with the patient, bearing in mind the
severity of symptoms against the scarring or discomfort
from treatment of a benign condition [2]. In patients with
large FAD or fast growing lesions, excision should be rec-
ommended [2, 3]. Minimally invasive ablative techniques
offer the opportunity to treat FAD without scarring and
the ability to image the progress during treatment. We
reviewed the current evidence of non- or minimally inva-
sive ablative techniques in the treatment of breast FAD.
High-intensity focused ultrasound
High-intensity focused ultrasound (HIFU) is a completely
non-invasive ablative technique (Fig. 1) [5]. During HIFU,
an ultrasound (US) beam generated by a piezoelectric US
transducer propagates through tissue as a high-energy
pressure wave [6]. The beam is focused onto the targeted
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tissue, and the energy from the beam elevates the
temperature up to 60–95 °C within a few seconds without
causing damage to direct adjacent tissues, allowing a fo-
cused ablation leading to protein denaturation and coagu-
lative necrosis [6, 7]. Seven studies have been performed of
which one is currently recruiting patients for a HIFU trial;
the protocols and/or results are summarised in Table 1.
Hynynen et al. [8] evaluated the feasibility of HIFU
using magnetic resonance imaging (MRI) guided HIFU
system (GE Medical Systems, Milwaukee, USA) for the
treatment of 11 FAD in nine patients (median 29, range
19–38 years) with a mean volume of 1.9 ± 1.5 cm3 (range
0.7–6.5 cm3). Complete response was defined as a de-
crease in volume of >90 %, partial response as a decrease
between 50–90 % and minor response as a decrease be-
tween 10 and 49 %. T1-weighted MRI showed complete
(n = 6), partial (n = 2), minor (n = 1) and no response (n = 2)
to HIFU treatment, and T2-weighted MRI showed a mean
volume decrease to 1.3 ± 1.1 cm3 at 6 months post-
treatment. On thermal imaging, hotspots of 73.6 % (743/
1010) of all sonications were visible and a temperature ele-
vation between 12.8 and 49.9 °C were seen in MRR im-
aging. Pain was recorded as slight (n = 4), moderate (n = 2)
or severe (n = 1). Tenderness was common up to 10 days
and oedema up to 2 days post-treatment.
Tempany et al. [9] evaluated the safety and efficacy of
HIFU treatment in 102 patients using the MRI-guided
InSightec device (GE Medical Systems, Milwaukee, USA).
The goal was to obtain a decrease in size of ≥50 % on
physical examination and ≥65 % on MRI. Inclusion cri-
teria were patients of ≥18 years with a histologically con-
firmed single FAD, visible on non-contrast MRI with a
size of ≥0.5 cm. Follow-up period was not documented.
Kovatcheva and Boulanger et al. [10] included 42 women
with 51 FAD in an uncontrolled open-label prospective
multicentre study using the Echopulse device (Theraclion
Ltd., Malakoff, France). Eight patients (19 %) received a
second treatment because symptoms persisted and/or vol-
ume reduction after 3 months post-treatment was ≤50 %.
Patients’ mean age was 32 years (range 16–52 years), and
average treatment time was 118 min (range 60–255 min).
Mean FAD volume on US was 3.89 ml (range 0.34–
19.66 ml), and a volume reduction of 33.2 % (SD 19.1 %)
was visible at 2 months, 59.2 % (SD 18.2 %, p < 0.001) at
6 months and 72.5 % (SD 16.7 %, p < 0.001) at 12 months.
Mean visual analogue pain scale at the end of treatment
was 29.7 ± 27.5 mm (range 0–80 mm). Post-treatment
complications were superficial skin burns (n = 3), hyper-
pigmentation (n = 1) and a palpable subcutaneous indur-
ation between the FAD and the skin (n = 1).
Cavallo Marincola et al. [11] presented the results of
using the model JC HIFU device in ten patients with breast
FAD. Patients’ mean age was 26 years (range 18–34 years),
and the treatment time between the first and last sonic-
ation was 57.2 min (range 40–100 min). At 3 months
follow-up, a 50 % reduction in maximum diameter was
seen on US. No adverse events were reported apart from
mild swelling and hardness of the treated area.
In the mono-centre, open-label uncontrolled study by
Hahn et al. [12], 27 patients were recruited to evaluate
the efficacy of HIFU using the Echopulse device (Thera-
clion Ltd., Malakoff, France). The secondary outcome
measure was the tolerability of HIFU treatment. Patients
were included if ≥18 years with at least one diagnosed
FAD based on triple assessment and a maximum diam-
eter of 2.5 cm. Patients were followed-up for 12 months.
Douek et al. [13, 14] performed a feasibility study of
50 patients to assess the treatment of FAD with a cir-
cumferential HIFU treatment using the Echopulse device
(Theraclion Ltd., Malakoff, France). The primary out-
come measure was the change in volume of FAD as re-
corded on US, and secondary outcome measures include
complications, patient-recorded outcome measures, mean
treatment time and cost-effectiveness of HIFU. Patients
were eligible if ≥18 years with FAD diagnosed according
to local hospital protocol, visible on US, and for patients
of ≥25 years, cytological or histological confirmation was
required. Patients were followed-up at 2 weeks, 3, 6 and
12 months.
Benin et al. [15] designed a FDA approved feasibility
study with 20 patients to determine the safety and effi-
cacy of the Echopulse device (Theraclion Ltd., Malakoff,
Fig. 1 Treatment overviews: (left) high-intensity focused ultrasound, (middle) cryo-ablation and (right) laser ablation [23, 33, 34]
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Table 1 High-intensity focused ultrasound (HIFU) ablation studies treating fibroadenomata
Study Number Size (cm) Age (years) Device Follow-up
(months)
Therapeutic efficacy Complications Time (min)
Hynynen (2001) 9 (11) 1.9 ± 1.5 cm3 (0.7–6.5)a 29 (19–38)b InSightec (transducer diameter
100 mm and radius curvature 80 mm)
6 (18–48) Complete necrosis (n = 6), partial
necrosis (n = 2), minor necrosis
(n = 1) and no response (n = 2)
Oedema, tenderness –
Tempany (2005) 102 – – InSightec (−) – – – –
Kovatcheva &
Boulanger (2014)
42 (51) 3.9 ml (0.3–19.7)a 32 (16–52)a EchoPulse (transducer diameter
60 mm, 3 MHz)
12 Reduction of 33.2 ± 19.1 % at
2 months, 59.2 ± 18.2 % at 6 months
and 72.5 ± 16.7 % at 12 months






10 – 26 (18–34)a JC HIFU (−) – 50 % reduction after in maximum




Hahn (2016) 27 – – EchoPulse (transducer diameter
60 mm, 3 MHz)
12 – – –
Douek (2016) 50 – – EchoPulse (transducer diameter
60 mm, 3 MHz)
12 – –
Brenin (2016) 20 – – EchoPulse (transducer diameter
60 mm, 3 MHz)
12 – –













France). Primary outcome measures were the change in
volume of the FAD measured by US, size of FAD on
physical examination, patient-recorded outcomes by
measuring patients rated pain and response to satisfac-
tion questionnaires. The secondary outcome measure
was the incidence of adverse events. Patients were eli-
gible if ≥18 years, with a palpable histological confirmed
FAD with a size ≥1 cm and volume between 2 and
10 cm3. Patients are followed-up at 3, 6 and 12 months.
In general, studies so far included small patient
numbers and none were controlled. Further patient
follow-up is required on existing studies. Post-treatment
complications were mild, and treatment times lasted be-
tween 1 and 2 h.
Cryo-ablation
Cryo-ablation uses freezing instead of heating in the treat-
ment of breast lesions (Fig. 1). Modern cryo-ablation has
been used for more than 20 years. It is accomplished by
inserting a cryo-probe under US guidance into the target
tissue. Liquid nitrogen or Argos gas is then inserted into
the cryo-probe allowing it to flow towards the target tis-
sue. The freezing process involves two phases: freezing
and thawing. Four mechanisms destroy the tumour cells:
direct damage by (1) intracellular ice crystal formation
resulting in disruption of cell membranes and (2) osmotic
dehydration and indirect damage by coagulation of blood
resulting into (3) ischemia and (4) immunologic response.
The treatment has good precision and control because
formation of the ice ball can be clearly visualised using US
[16, 17]. Seven studies performed trials or have published
results of trials using cryo-ablation in the treatment of
FAD. These studies are summarised in Table 2.
Klein et al. [18] performed a study with 54 patients to
determine whether the ice-sense cryo-ablation system
(IceCure Medical Ltd., Tel Aviv, Israel) was safe and ef-
fective in the treatment of benign breast lesions like
FAD. The outcome measures were engulfment of the
iceball, as seen on US, and adverse events. Patients were
eligible if ≥18 years, with histologically proven FAD, vis-
ible on US and a size between 0.5 and 3.0 cm. Follow-up
was performed for 12 months.
Golatta et al. [19] performed the multicentre open-
labelled non-randomised CRYSTAL study using the Ice-
Sense3 (IceCure Medical, Caesarea, Israel) in the treatment
of FAD. Data was collected from 60 procedures using a
freeze-thaw-freeze technique, with 58 cases completing a
12-month follow-up. Engulfment of the lump was achieved
in 98.3 % with an average first freezing cycle of 1.44 min
and second cycle of 1.30 min. One mild and resolved ad-
verse event (induration of the patient’s breast) occurred.
Prior to treatment, 76 % (46/60 cases) of FAD were palp-
able. Twenty-eight percent (17/60 cases) reported mild to
moderate pain prior to treatment. At 1 year, 22 % (13/58
cases) were palpable and 2 % (1/58 cases) reported mild
to moderate pain. Cosmetic results were described as
good–excellent in 100 % by physicians and 97 % by pa-
tients. Mean FAD volume was 1.2 cm3 (SD 0.9 cm3)
prior to treatment, and FAD were completely resolved
in 93 % at 1 year post-treatment.
Kaufman et al. performed a prospective non-randomised
trial using cryo-ablation in the treatment of benign breast
lesions. One article [20] described all included patient re-
sults, and three articles [21–23] described the results of pa-
tients with FAD. The mean age of 57 patients with 70 FAD
who were included (mean ± SD (range)) was 35 ± 13 years
(13–66 years). Patients were eligible if evaluated by physical
examination, mammography, ultrasound and histology
confirming the diagnosis. The Visica device (Sanarus Med-
ical, Pleasanton, California) was used with a freeze-thaw-
freeze technique. The mean treated lesion diameter as seen
on US was 2.1 ± 0.08 cm (range 0.7–4.2 cm). At 12 months,
11 % of median tumour volume was remaining and 75 %
of tumours became non-palpable. A good or excellent
cosmesis was achieved in 91 % at 12 months and unsatis-
factory in 9 %. Post-operative complications were local
swelling (all), ecchymosis (all), moderate to severe pain
(n = 2), mild hematoma (n = 32), mild skin injury (n = 4),
minor tape blisters (n = 7), minor pigmentation of the skin
(n = 3), keloid at puncture side (n = 2) and transient nipple
retraction (n = 1). Long-term follow-up [22] (2.6 years
(range 1.3–3.8 years)) in 29 patients (32 FAD) showed
palpability decrease from 84 % initially to 16 % at the most
recent follow-up. On US, the median reduction in volume
of the residual FAD debris was 89 % at 12 months and
99 % at the most recent follow-up. Two types of complica-
tions were reported (n = 2) and cyclic focal pain (n = 1).
Overall satisfaction (scales 1–5) by physicians was on aver-
age 4.8 and 4.6 by patients. Cosmesis was 100 % by both
patients and physicians.
A multicentre trial by Edwards et al. [24] used the Visica
cryo-ablation system (Sanarus Medical, Pleasanton,
California). Two freeze-thaw cycles were used, and follow-
up was performed at 6 and 12 months. At 53 sites, 310
FAD were treated with a mean diameter of 1.8 cm. FAD
were palpable at pre-treatment in 77 %, post-treatment at
3 months 50 % and at 6 months in 33 % of patients. Aver-
age residual lesion volume was 49 % at 6 and 3 % at
12 months. Complications were infection (2 %), ecchym-
osis (unknown), hematoma (amount comparable to surgi-
cal excision), tape blisters (5 %) and depigmentation (1 %).
Ninety-two percent of patients were satisfied with the pro-
cedure and 91 % would recommend treatment.
Littrup et al. [25] performed a study with 29 patients
and 42 FAD to assess imaging and clinical outcomes of
cryo-ablation for breast FAD. The US guided Visica treat-
ment system (Sanarus Medical, Pleasanton, California)
was used with a freeze-thaw-freeze cycle. Mean patient
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Table 2 Cryo-ablation studies treating fibroadenomata
Study Number Size (cm)a Age (years)a Device type Therapeutic efficacy Complications Follow-up
(months)a
Time (min)a
Caleffi (2004) 102 (124) 1.4 ± 0.6 vs
2.1 ± 0.8
38 (45 vs 34 ± 13) Visica, 2.4 mm cryo-needle,
−160 °C
Double HI-Freeze 67 % still
palpable after 12 months,
Tailored freeze volume reduction
91 % after 12 months
Tape blisters (n = 6),
keloid (n = 2), ecchymosis,
discomfort, oedema
12 16.1 vs 14.7 ± 3.3
Littrup (2005) 29 (42) 4.2 ± 4.7 26.6 (13–50) Visica, 2.4 mm cryo-needle,
−187 °C
Reduction in tumour volume
73 % after 12 months
Hypo-pigmentation (n = 3) 12 –
Kaufman (2004) 57 (70) 2.1 (0.7–4.2) 35 ± 13 (13–66) Visica, 2.4 mm cryo-needle,
−186 °C
Reduction in tumour volume
89 % after 12 months
Moderate-severe pain (n = 2),
hematoma (n = 2), skin injury
(n = 4), tape blisters (n = 7),
pigmentation (n = 3), keloid
(n = 2), nipple retraction (n = 1)
12 14.8 ± 3.3
Kaufman (2005) 29 (32) 2.1 ± 0.8
(0.8–4.2)
35 (13–66) Visica, 2.4 mm cryo-needle,
−186 °C
Median reduction in tumour
volume 89 % at 12 months
and 99 % at most recent
follow-up





444 1.8 – Visica, 2.7 mm cryo-probe,
−160 °C
Mean reduction in tumour
volume 51 % after 6 months




60 1.2 ± 0.9 cm3 – IceSense3, up to 3.5 mm
cryo-probe, −196 °C
Completely resolved FAD
93 % after 12 months
Induration of breast (n = 1) 12 –












age was 26.6 years (range 13–50 years) with an average
volume of 4.2 ± 4.7 cm. At 6 months, four FAD showed
‘fragmentation’ and at 12 months, five FAD could no
longer be identified. A reduction of 73 % to 0.7 ± 0.8 cm
(P < 0.001) was found. All patients were happy with the
cosmesis, and in three patients, scarring at the insertion
site leads to hypo-pigmentation which resolved between 6
and 12 months. One patient developed a keloid and at the
end of the trial, two patients underwent surgical excision.
Caleffi et al. [26] used the Visica system (Sanarus Medical,
Pleasanton, California) to carry out interstitial US-guided
cryo-ablation of 124 benign breast lesions in 102 patients.
The Double HI-Freeze technique was used for 42 breast
lesions (unknown amount of FAD) with mean age 45 years
and mean size 1.4 ± 0.6 cm; patients were treated within an
average 16.1 min. The Freeze technique was used in 82
breast lesions (70 FAD, five fibrocystic changes and seven
other benign changes) with mean age 34 ± 13 years, mean
size 2.1 ± 0.8 cm and a mean time of 14.7 ± 3.3 min. Within
the Double HI-Freeze group, 14 lumps were palpable pre-
treatment and at 1 year post-treatment, 67 % (24/36 le-
sions) were palpable. Within the Tailored freeze group, a
volume reduction of 91 % at 12 months was visible. Re-
ported complication were ecchymosis, discomfort, oedema,
tape blisters (n = 6) and keloid (n = 2). Patient satisfaction
was excellent in 92 % of patients.
Nurko et al. [27] developed the multicentre FibroAden-
oma Cryoablation Treatment (FACT) trial to evaluate the
cryo-ablation technique. The Visica treatment system
(Sanarus Medical, Pleasanton, California) was used with a
freeze-thaw-freeze technique. Four hundred forty-four
FAD were treated with a mean diameter of 1.8 cm. Prior
to cryo-ablation, 75 % of FAD were palpable and 100 %
were visible on US. At 6 months, 46 % of cases (110/237)
were palpable and 36 % (79/219) visible on US and at
12 months, 35 % of cases (29/82) were palpable and 29 %
visible on US (21/71). Mean treatment time was 31 min
with a mean freezing time of 22 min. At 6 and 12 months,
acute complications (no details reported) had resolved
without consequences apart from residual pain in 15 %
(37/242 cases) at 6 months, and 25 % (22/87 cases) at
12 months. Patient satisfaction was 91 % (216/235 cases)
at 6 months and 88 % (74/84 cases) at 12 months.
In general, the cryo-ablation studies contained larger
numbers compared to HIFU. Post-treatment complica-
tions were more serious but less frequent compared to
HIFU and treatment times were about 15 min.
Laser ablation
In laser ablation (Fig. 1), lesions are destroyed using direct
heating with low-power laser light energy delivered via
thin optical fibres which are percutaneously inserted
under US or MRI guidance [28]. Upon absorption in the
tissue, heat is produced, inducing lethal thermal injury by
changing the optical characteristics of the tissue [29]. The
level of necrosis is dependent on the temperature and the
ablation time. Laser ablation can induce very precise ne-
crosis. The size and shape of thermal lesions are difficult
to predict, however owing to biologic variability, fibre tip
charring and changing optical and thermal properties of
the tissue during interstitial laser photocoagulation [28].
Three studies have been performed, of which one is cur-
rently collecting data, for trials using laser ablation in the
treatment of FAD (Table 3).
DeLay et al. [30] performed an observational study to
monitor long-term safety and effectiveness of the Novi-
lase device (Novian Health Ltd., Chicago, USA) in 500
patients. Patients were included if ≥18 years with core
needle biopsy confirmed FAD, detected either by phys-
ical examination or imaging, ≤2 cm in diameter and lo-
cated ≥0.5 cm away from the skin and chest wall. No
follow-up period was reported.
Basu et al. [31] included 27 patients in an uncon-
trolled prospective study to evaluate the effects of inter-
stitial laser hyperthermia in FAD of the breast. For the
procedure, the Lasermatic (model 5050–23, Combolaser,
Helsinki, Finland) was used with ND:YAG bare quartz
fibres of 600 μ in diameter. Mean age was 21.8 years
(14–35 years). All patients experienced a warm sensation
locally during the procedure, and immediately post-
treatment US showed a hyper-echoic zone with a narrow
rim of hypo-echogenicity (0.3–0.5 cm). Blanching of the
Table 3 Laser ablation studies treating fibroadenomata




Basu (1999) 27 <2 21.8 (14–35) Nd:YAG (1064 nm,









Lai (1999) 24 (29) 2.5 (1.4–3.5) 26 (18–42) Diomed 25
(805 nm, 2.5 W)
Mean reduction in size
38 % after 3 months,
60 % after 6 months and
100 % after 12 months
Discomfort, swelling and
tenderness (n = 20), bruising
(n = 4), skin burn (n = 3),
oily discharge (n = 1)
12 –
DeLay (2008) 500 – – Novilase – – – –
aMean (range)
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skin at the needle insertion site was seen in eight patients,
followed by skin breakdown and hyperpigmentation dur-
ing follow-up. At 2 weeks, all lumps were tender and less
mobile and US showed a decrease in size and a narrower
hypo-echoic rim. At 4 weeks, US showed a heterogeneous
echo pattern and at 8 weeks, further reduction of the
lump was seen. Histopathology in ten patients showed
fibrotic tissue, and a decrease in size was found clinically
(60–70 % reduction, mean 2.6 ± 0.8 cm to 1.3 ± 0.6 cm)
and on US (40 50 % reduction, mean 2.2 ± 1.0 cm to 0.7 ±
0.4 cm).
Lai et al. [32] evaluated the feasibility of laser ablation
using the semiconductor diode laser (Diomed 25, Diomed
Ltd., Cambridge, UK) as a minimal invasive technique for
FAD. Twenty-four patients with 29 FAD were treated with
a median age of 26 years (18–42 years) and medium size
of 2.5 cm (1.4–3.5 cm). Size reduction was seen in 28
lesions, and six patients had surgical excision post-
treatment. Median reduction in size was 38 % at 3 months,
60 % at 6 months and 100 % at 12 months. Lumps were
no longer palpable and no FAD increased in size. In 11/17
lesions which showed strong enhancement on pre-MRI,
zones of non-enhancement post-treatment were visible.
Reported complications were discomfort, local swelling
and tenderness (n = 20), bruising (n = 4), small skin burn
around needle insertion point (n = 3) and a persistent oily
discharge for 3 weeks (n = 1).
In general, data on laser ablation therapy is available
from only a few studies although these included reasonable
numbers of patients. Post-treatment complications were
frequent and severe compared to HIFU and cryo-ablation.
Treatment times were quick, approximately 5 min.
Discussion
The use of minimally invasive techniques like laser, cryo-
and HIFU ablation enables the patient to undergo treat-
ment without surgery and general anaesthesia and the risk
of complications accompanied with the currently used
techniques. Further advantages are the possibility of defin-
ing the target intraoperatively, an absence of scarring and
therefore an improved cosmesis and reduced recovery
time which could result in economic benefits. The disad-
vantage is that the FAD is not removed but will gradually
decrease in size in the months following treatment. Pa-
tients must therefore be well informed to prevent anxiety
regarding the lump. Furthermore, histological confirm-
ation cannot be obtained during treatment as no specimen
is removed. Histological diagnosis and a treatment plan
should therefore be obtained before ablative treatment. If
no histology is obtained in advance, a risk exists that the
lesion might actually be a malignant lesion or other
benign condition.
Objectively, only the cryo-ablation and laser ablation
techniques can be compared since for HIFU only three
out of seven studies have currently published results, and
one trial has presented preliminary results. For cryo-
ablation, six of seven studies, and in laser ablation, two of
three studies, have published results. Large trials are re-
quired to objectively compare these minimally invasive
techniques.
Looking at the efficacy of the treatment, in HIFU [8], a
decrease in volume of 32 % was seen after 6 months. In
cryo-ablation [20, 24–26], there was a mean decrease in
volume of 40.6 % at 6 months and 87.3 % at 12 months.
For laser ablation [32], the mean decrease in size was 60 %
at 6 months and 100 % at 12 months. Therefore, laser
ablation shows the best potential. However, due to the
limited amount of results and the inhomogeneity of the
trials, no conclusions can be made. The lower volume
reduction seen with HIFU can be explained by the ab-
sence of a needle or probe inserted into the FAD which
directly heats or cools the surrounding tissue. With HIFU,
due to this absence, there is greater care needed to avoid
injury to surrounding tissues or the skin.
Complications such as oedema, pain, tenderness and
bruising are common in all techniques; tape blisters,
hamartoma and keloids occur in cryo-ablation; and the
tape blisters result in depigmentation of the skin near
the needle insertion point. In laser ablation, skin burns
were more common; however, these could occur in
HIFU as well.
In general, no distinct difference can be identified be-
tween the three techniques; efficacy and complications are
similar in all techniques from these preliminary series.
More results, from large trials, are needed to give more
conclusive outcomes.
Conclusions
Minimally invasive ablative techniques like HIFU, cryo-
ablation and laser ablation are promising in the treat-
ment of breast FAD. Future trials should be randomised
and contain larger numbers of patients to determine the
effectiveness of ablative techniques with more precision.
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